Ocular Complications After Anti–Vascular Endothelial Growth Factor Therapy in Medicare Patients With Age-Related Macular Degeneration
- 31 August 2011
- journal article
- Published by Elsevier BV in American Journal of Ophthalmology
- Vol. 152 (2), 266-272
- https://doi.org/10.1016/j.ajo.2011.01.053
Abstract
No abstract availableKeywords
Funding Information
- University of Washington
- Genentech
- National Institute on Aging
- National Institutes of Health
This publication has 25 references indexed in Scilit:
- Intravitreal Bevacizumab and Ranibizumab for Age-Related Macular Degeneration: A Multicenter, Retrospective StudyOphthalmology, 2010
- Risk of Endophthalmitis After Intravitreal Drug Injection When Topical Antibiotics Are Not RequiredJAMA Ophthalmology, 2009
- EVALUATION OF SAFETY FOR BILATERAL SAME-DAY INTRAVITREAL INJECTIONS OF ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR THERAPYRetina, 2009
- INFECTIOUS ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION OF ANTIANGIOGENIC AGENTSRetina, 2009
- SAFETY OF REPEAT INTRAVITREAL INJECTIONS OF BEVACIZUMAB VERSUS RANIBIZUMABRetina, 2009
- INCIDENCE OF ENDOPHTHALMITIS RELATED TO INTRAVITREAL INJECTION OF BEVACIZUMAB AND RANIBIZUMABRetina, 2008
- Ranibizumab for Neovascular Age-Related Macular DegenerationThe New England Journal of Medicine, 2006
- A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo studyStatistics in Medicine, 2006
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987
- The central role of the propensity score in observational studies for causal effectsBiometrika, 1983